Concepedia

Brett Lauring

BL

30

Publications

2.8K

Citations

24

H-Index

1995

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Columbia University

Memorial Sloan Kettering Cancer Center

New York University

Brett Lauring is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cell biology, and molecular biology.

ORCID

Top concepts

Publications per year

1995–2019

30

Publications

30

Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing

Katia J. Evans, Edgar R. Gomes, Steven M. Reisenweber et al. · The Journal of Cell Biology · 2005 · 220 citations · Full text

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley et al. · American Heart Journal · 2018 · 202 citations · Full text

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( <scp>VERTIS MET</scp> )

Julio Rosenstock, Juan P. Frías, Dénes Páll et al. · Diabetes Obesity and Metabolism · 2017 · 184 citations · Full text

Recognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severing

Susan Roehl White, Katia J. Evans, Jeffrey W. Lary et al. · The Journal of Cell Biology · 2007 · 171 citations · Full text

, , +17

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial

Richard E. Pratley, Roy Eldor, Annaswamy Raji et al. · Diabetes Obesity and Metabolism · 2017 · 158 citations · Full text

Rows per page

1–5 of 30